MAHMOOD ZAMANIAN: Open Payments
NPI 1386641876 · ALBUQUERQUE, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$733 in 40 payments from 15 companies in 2025. Trend: 2023 $285 · 2024 $614 · 2025 $733
Food & beverage: $733
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $141 |
| Otsuka America Pharmaceutical, Inc. | 6 | $112 |
| Lilly USA, LLC | 4 | $88 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
| PFIZER INC. | 3 | $57 |
| GlaxoSmithKline, LLC. | 3 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Astellas Pharma US Inc | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
Products named: REXULTI, EVENITY, Kerendia, JARDIANCE, XIFAXAN, ELIQUIS, OTEZLA, Veozah.
Industry payments across NM — which companies pay providers there.
